2333 related articles for article (PubMed ID: 21726934)
1. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
2. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.
Mirone V; Sessa A; Giuliano F; Berges R; Kirby M; Moncada I
Int J Clin Pract; 2011 Sep; 65(9):1005-13. PubMed ID: 21718399
[TBL] [Abstract][Full Text] [Related]
3. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
Lowe FC
BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
[TBL] [Abstract][Full Text] [Related]
4. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
Miner M; Rosenberg MT; Perelman MA
Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
[TBL] [Abstract][Full Text] [Related]
5. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia.
Rosen RC
Curr Opin Urol; 2006 Jan; 16(1):11-9. PubMed ID: 16385195
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
Martínez-Salamanca JI; Carballido J; Eardley I; Giuliano F; Gratzke C; Rosen R; Salonia A; Stief C
Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
[TBL] [Abstract][Full Text] [Related]
7. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
Seftel A; Rosen R; Kuritzky L
Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
Wang C
Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943
[TBL] [Abstract][Full Text] [Related]
9. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Rosen RC; Giuliano F; Carson CC
Eur Urol; 2005 Jun; 47(6):824-37. PubMed ID: 15925080
[TBL] [Abstract][Full Text] [Related]
10. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
[TBL] [Abstract][Full Text] [Related]
11. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
Miller MS
Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
[TBL] [Abstract][Full Text] [Related]
12. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Carson CC
BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
[TBL] [Abstract][Full Text] [Related]
13. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
14. BPH/LUTS and ED: common pharmacological pathways for a common treatment.
Fusco F; D'Anzeo G; Sessa A; Pace G; Rossi A; Capece M; d'Emmanuele di Villa Bianca R
J Sex Med; 2013 Oct; 10(10):2382-93. PubMed ID: 23875757
[TBL] [Abstract][Full Text] [Related]
15. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry.
Rosen RC; Wei JT; Althof SE; Seftel AD; Miner M; Perelman MA;
Urology; 2009 Mar; 73(3):562-6. PubMed ID: 19167031
[TBL] [Abstract][Full Text] [Related]
16. PDE5 inhibitors for LUTS.
Mouli S; McVary KT
Prostate Cancer Prostatic Dis; 2009; 12(4):316-24. PubMed ID: 19687801
[TBL] [Abstract][Full Text] [Related]
17. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
19. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
20. Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link.
Rosen RC; Seftel AD
Int J Impot Res; 2008 Dec; 20 Suppl 3():S27-32. PubMed ID: 19002122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]